The health technology assessment system in Australia
https://doi.org/10.17749/2070-4909.2019.12.4.333-341
Abstract
In Australia, the federal government is in charge of providing the health care to patients. The government agencies determine the list of reimbursable pharmaceuticals and medical services and also define the preferential categories of the population. The states and territories may have their own health care programs in addition to the federal ones. The Pharmaceutical Benefits Advisory Committee (PBAC) is responsible for the health technology assessment (HTA) and decides which technology is eligible for reimbursement by the federal budget. The drug evaluation process includes five stages: a review of general information about the product, assessment of its clinical efficacy, cost-effectiveness analysis, assessment of financial implications of including the drug in the reimbursement list, and consideration of any other factors that may influence the committee decision. In addition to the full reimbursement of pharmaceuticals, the committee may decide to provide funding based on a managed entry agreement.
About the Authors
V. V. Omelyanovskiy
Financial Research Institute of the Ministry of Finance of the Russian Federation; Russian Presidential Academy of National Economy and Public Administration
Russian Federation
Russian Federation
Vitaly V. Omelyanovskiy – MD, PhD, Professor, Head of the Center for Healthcare Funding, Financial Research Institute of the Ministry of Finance of Russia; Head of the Laboratory for Health Technology Assessment at the Institute of Applied Economic Research, Russian Presidential Academy of National Economy and Public Administration (RANEPA).
Researcher ID: P-6911-2018
Scopus Author ID: 6507287753
3-2 Nastasyinsky pereulok, Moscow 127006
82 Vernadskogo prospect, Moscow 119571
E. S. Saybel
Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Yegor S. Saybel – PhD, Lead Specialist, Center for Healthcare Quality Assessment and Control, Ministry of Health of the Russian Federation.
10-5 Khokhlovskii pereulok, Moscow 109028
T. P. Bezdenezhnykh
Financial Research Institute of the Ministry of Finance of the Russian Federation; Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Tatiana P. Bezdenezhnykh – Lead Specialist, Center for Healthcare Quality Assessment and Control, Ministry of Health of the Russian Federation; Junior Researcher at the Center for Healthcare Funding, Financial Research Institute of the Ministry of Finance of Russia.
3-2 Nastasyinsky pereulok, Moscow 127006
10-5 Khokhlovskii pereulok, Moscow 109028
G. R. Khachatryan
Financial Research Institute of the Ministry of Finance of the Russian Federation; Center for Healthcare Quality Assessment and Control of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Georgii R. Khachatryan – Head of the Department of Methodological Support of Comprehensive Health Technology Assessment, Center for Healthcare Quality Assessment and Control, Ministry of Health of the Russian Federation; Junior Researcher at the Center for Healthcare Funding, Financial Research Institute of the Ministry of Finance of Russia.
3-2 Nastasyinsky pereulok, Moscow 127006
10-5 Khokhlovskii pereulok, Moscow 109028
References
1. Official website of the Australian Government. [Electronic resource] URL: https://www.australia.gov.au/about-government/how-government-works/federation. Accessed: 09.10.2019.
2. Mirror, Mirror 2017: International Comparison Reflects Flaws and Opportunities for Better U.S. Health Care. July 13, 2017. By: Eric C. Schneider, M.D.: Dana O. Sarnak: David Squires: Arnav Shah: Michelle M. Doty. [Electronic resource] URL: https://interactives.commonwealthfund.org/2017/july/mirror-mirror/. Accessed: 09.10.2019.
3. Australian Government Australian Institute of Health and Welfare. [Electronic resource] URL: https://www.aihw.gov.au/reports/health-welfare-expenditure/health-expenditure-australia-2016-17/contents/summary. Accessed: 09.10.2019.
4. Mossialos E. et al. International profiles of health care systems. 2015. The Commonwealth Fund, January 2016. [Electronic resource] URL: https://international.commonwealthfund.org/countries/australia/. Accessed: 09.10.2019.
5. Expenditure and Prescriptions Twelve Months to 30 June 2017. PBS Information Management Section Pricing and Policy Branch Technology Assessment and Access Division. [Electronic resource] URL: http://www.pbs.gov.au/statistics/expenditure-prescriptions/2016-2017/expenditure-and-prescriptions-twelve-months-to-30-june-2017.pdf. Accessed: 09.10.2019.
6. Official website of the Australian Department of Health. [Electronic resource] URL: https://beta.health.gov.au/about-us/the-australian-health-system Accessed: 09.10.2019.
7. Official site of the Australian Tax Administration. [Electronic resource] URL: https://www.ato.gov.au/Individuals/Medicare-levy/. Accessed: 09.10.2019.
8. Official website of the Ombudsman for Private Insurance. [Electronic resource] URL: https://www.privatehealth.gov.au/health_insurance/howitworks/index.htm. Accessed: 09.10.2019.
9. About the program of preferential drug provision. [Electronic resource] URL: http://www.pbs.gov.au/info/about-the-pbs#What_is_ the_RPBS. Accessed: 09.10.2019.
10. Australian Department of Health Annual Report. [Electronic resource] URL: https://beta.health.gov.au/resources/publications/department-of-health-annual-report-2017-18. Accessed: 09.10.2019.
11. Australian Medicines Administration Official Website. [Electronic resource] URL: https://www.tga.gov.au/sme-assist/overview-applying-market-authorisation. Accessed: 09.10.2019.
12. Procedure guidance for listing medicines on the Pharmaceutical Benefits Scheme (including consideration of vaccines for the National Immunisation Program). Australian Government Department of Health. Version 1.3. September 2018.
13. Senate Community Affairs Reference Committee. Availability of new, innovative and specialist cancer drugs in Australia. Final Report. September. 2015.
14. The Pharmaceutical Benefits Advisory Committee of Australia. [Electronic resource] URL: https://www.pbs.gov.au/pbs/industry/listing/participants/pbac. Accessed: 09.10.2019.
15. Australian Government. Department of Health. The Pharmaceutical Benefits Scheme. Procedure guidance for listing medicines. [Electronic resource] URL: http://www.pbs.gov.au/industry/listing/procedure-guidance/files/Procedure-Guidance-Listing-Medicines-on-the-PBS-v1-6.pdf. Accessed: 09.10.2019.
16. Henry D.A., Hill S.R. & Harris A. Drug Prices and Value for Money. JAMA: The Journal of the American Medical Association. 2005; 294: 2630-2632.
17. George B., Harris A. & Mitchell A. Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996). Pharmacoeconomics. 2001; 19: 1103-9.
18. Harris A. H., Hill S. R., Chin G., Li J. J. & Walkom E. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Medical Decision Making. 2008; 28: 713-22.
19. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Version 5.0 September 2016. [Electronic resource] URL: https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf. Accessed: 09.10.2019.
20. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 1. [Electronic resource] URL: https://pbac.pbs.gov.au/section-1-context.html. Accessed: 09.10.2019.
21. Robinson M. F. et al. Characteristics of managed entry agreements in Australia. International journal of technology assessment in health care. 2018; 34 (1): 46-55.
22. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 2. [Electronic resource] URL: https://pbac.pbs.gov.au/section2-clinical-evaluation.html. Accessed: 09.10.2019.
23. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 3. [Electronic resource] URL: https://pbac.pbs.gov.au/section-3-economic-evaluation.html. Accessed: 09.10.2019.
24. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 4. [Electronic resource] URL: https:// pbac.pbs.gov.au/section-4-use-of-the-medicine-in-practice.html. Accessed: 09.10.2019
25. Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee Section 5. [Electronic resource] URL: https://pbac.pbs.gov.au/section-5-options-to-present-additional-relevant-information.html. Accessed: 09.10.2019.
26. Australian Government. Department of Health. 7.1 Notification of outcomes of PBAC. [Electronic resource] URL: http://www.pbs.gov.au/info/industry/listing/procedure-guidance/7-post-pbac-decision-procedures-sponsors/7-1-notification-of-outcomes-of-pbac. Accessed: 09.10.2019.
27. PBS Calendars. [Electronic resource] URL: http://www.pbs.gov.au/info/industry/useful-resources/pbs-calendar. Accessed: 09.10.2019.
28. Paris V., Belloni A. Value in pharmaceutical pricing country profile: Australia. OECD Health Working Papers. 2014. №63.
29. Formulary Allocations. Australian Government. Department of Health. [Electronic resource] URL: http://www.pbs.gov.au/info/industry/pricing/pbs-items/formulary-allocations. Accessed: 09.10.2019.
30. Pharmaceutical Benefits Scheme Post-market Reviews Information for Stakeholders. [Electronic resource] URL: http://www.pbs.gov.au/reviews/subsidised-medicines-reviews-files/post-market-review-framework-10-2014.pdf. Accessed: 09.10.2019.
Review
For citations:
Omelyanovskiy V.V., Saybel E.S., Bezdenezhnykh T.P., Khachatryan G.R. The health technology assessment system in Australia. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2019;12(4):333-341. (In Russ.) https://doi.org/10.17749/2070-4909.2019.12.4.333-341
Views: 1546
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 